TGTX · XBRL financial data

TG Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TGTX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	0	7	3	—	—	—
Revenue from contracts with customers	—	7	3	234	329	616
Cost of goods and services sold	—	1	0	14	38	101
Research and development	166	223	125	76	94	160
Selling, general and administrative	108	128	70	123	154	232
General and administrative	108	—	—	—	—	—
Total operating expenses	274	351	196	—	—	—
Operating income (loss)	(274)	(345)	(193)	21	42	123
Interest expense	6	6	10	13	24	27
Other income (expense)	—	2	5	5	8	11
Income tax expense (benefit)	0	0	0	0	2	(340)
Net income (loss)	—	(348)	(224)	13	23	447
Earnings per share, basic USD per share	(2.42)	(2.63)	(1.46)	0.09	0.16	3.10
Earnings per share, diluted USD per share	(2.42)	(2.63)	(1.46)	0.09	0.15	2.77
Weighted average shares, basic millions of shares	115	132	135	142	145	144
Weighted average shares, diluted millions of shares	115	132	135	149	160	161

Fiscal years (TGTX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	553	299	102	93	180	79
Short-term investments	52	16	59	125	131	63
Accounts receivable	—	—	0	51	129	306
Inventory	—	—	0	40	110	126
Total current assets	612	331	168	318	566	631
Property and equipment, net	0	1	0	0	—	—
Right-of-use asset	9	9	9	8	7	6
Goodwill	1	1	1	1	—	—
Total assets	626	380	194	330	578	1,063
Current portion of long-term debt	22	1	0	—	—	—
Total current liabilities	88	65	53	54	91	154
Long-term debt	8	67	71	100	244	246
Lease liability, non-current	10	10	10	9	8	7
Total liabilities	106	142	135	169	355	415
Accumulated deficit	(981)	(1,329)	(1,527)	(1,514)	(1,529)	(1,082)
Total stockholders' equity	519	237	59	161	222	648
Total liabilities and equity	626	380	194	330	578	1,063
Common shares outstanding (cover page) millions of shares	141	143	146	154	157	160

Fiscal years (TGTX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	(348)	(224)	13	23	447
Stock-based compensation	80	61	19	38	43	65
Depreciation and amortization	—	0	0	0	0	0
Net cash from operating activities	(215)	(296)	(176)	(31)	(41)	(25)
Purchases of property and equipment	0	0	0	0	0	0
Net cash from investing activities	(25)	(0)	(20)	(51)	(1)	14
Proceeds from issuing common stock	—	2	0	46	0	0
Net cash from financing activities	680	41	(0)	73	129	(90)
Net change in cash	441	(255)	(197)	(9)	87	(101)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Cytokinetics	203	48	not reported	139.3M	—	Q3 FY26 10-QSep 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Summit Therapeutics	151	not reported	not reported	799.8M	—	Q3 FY26 10-QSep 30, 2026
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Acadia Pharmaceuticals	385	308	101*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Protagonist Therapeutics	420	213	219*	64.7M	—	Q2 FY26 10-QJun 30, 2026
Prestige Consumer Healthcare	89	266	71	47.4M	—	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.